The major clinical implication so far described in SRG mutations relates to the high frequency (37%) of lung carcinoma (mostly of the adenocarcinoma type) alone (12%) or in combination with pulmonary fibrosis (25%) in SFTPA1/SFTPA2 adult carriers. This evidence concerns the gene SFTPA2 and adenocarcinoma.